| Dr Lara Bakhos, MD | |
|
3825 Highland Ave, Downers Grove, IL 60515-1552 | |
| (630) 719-4799 | |
| Not Available |
| Full Name | Dr Lara Bakhos |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 18 Years |
| Location | 3825 Highland Ave, Downers Grove, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730336652 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 036123801 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Advocate Good Samaritan Hospital | Downers grove, IL | Hospital |
| Loyola University Medical Center | Maywood, IL | Hospital |
| Elmhurst Memorial Hospital | Elmhurst, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advocate Health And Hospitals Corporation | 7810800935 | 2422 |
News Archive
Now, new research by scientists at the University of Michigan Medical School suggests the intriguing possibility that this common virus also may play a role in prostate cancer – the second-leading cause of deaths from cancer in American men.
Efforts to understand costs and openly share information on healthcare prices played a key role in a major Arizona health system's successful turnaround from a financial crisis, according to a feature article in the Spring issue of Frontiers of Health Services Management, an official publication of the American College of Healthcare Executives.
Genalyte, Inc. announced today it has completed a Series C Financing round of $44 million, led by Khosla Ventures. The company is redefining diagnostics with a testing platform and microchip technology that can be utilized in physician offices. With the application of a single drop of blood to a silicon microchip, Genalyte's Maverick Detection System can offer a complete panel of diagnostic test results in fifteen minutes.
ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its fourth quarter and the fiscal year ended December 31, 2010.
Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.
› Verified 9 days ago
| Entity Name | Advocate Health And Hospitals Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700824455 PECOS PAC ID: 7810800935 Enrollment ID: O20031106000064 |
News Archive
Now, new research by scientists at the University of Michigan Medical School suggests the intriguing possibility that this common virus also may play a role in prostate cancer – the second-leading cause of deaths from cancer in American men.
Efforts to understand costs and openly share information on healthcare prices played a key role in a major Arizona health system's successful turnaround from a financial crisis, according to a feature article in the Spring issue of Frontiers of Health Services Management, an official publication of the American College of Healthcare Executives.
Genalyte, Inc. announced today it has completed a Series C Financing round of $44 million, led by Khosla Ventures. The company is redefining diagnostics with a testing platform and microchip technology that can be utilized in physician offices. With the application of a single drop of blood to a silicon microchip, Genalyte's Maverick Detection System can offer a complete panel of diagnostic test results in fifteen minutes.
ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its fourth quarter and the fiscal year ended December 31, 2010.
Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.
› Verified 9 days ago
| Entity Name | Elmhurst Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548306343 PECOS PAC ID: 3577458009 Enrollment ID: O20040216000346 |
News Archive
Now, new research by scientists at the University of Michigan Medical School suggests the intriguing possibility that this common virus also may play a role in prostate cancer – the second-leading cause of deaths from cancer in American men.
Efforts to understand costs and openly share information on healthcare prices played a key role in a major Arizona health system's successful turnaround from a financial crisis, according to a feature article in the Spring issue of Frontiers of Health Services Management, an official publication of the American College of Healthcare Executives.
Genalyte, Inc. announced today it has completed a Series C Financing round of $44 million, led by Khosla Ventures. The company is redefining diagnostics with a testing platform and microchip technology that can be utilized in physician offices. With the application of a single drop of blood to a silicon microchip, Genalyte's Maverick Detection System can offer a complete panel of diagnostic test results in fifteen minutes.
ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its fourth quarter and the fiscal year ended December 31, 2010.
Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.
› Verified 9 days ago
| Entity Name | Edward Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013969013 PECOS PAC ID: 0042108110 Enrollment ID: O20040309001279 |
News Archive
Now, new research by scientists at the University of Michigan Medical School suggests the intriguing possibility that this common virus also may play a role in prostate cancer – the second-leading cause of deaths from cancer in American men.
Efforts to understand costs and openly share information on healthcare prices played a key role in a major Arizona health system's successful turnaround from a financial crisis, according to a feature article in the Spring issue of Frontiers of Health Services Management, an official publication of the American College of Healthcare Executives.
Genalyte, Inc. announced today it has completed a Series C Financing round of $44 million, led by Khosla Ventures. The company is redefining diagnostics with a testing platform and microchip technology that can be utilized in physician offices. With the application of a single drop of blood to a silicon microchip, Genalyte's Maverick Detection System can offer a complete panel of diagnostic test results in fifteen minutes.
ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its fourth quarter and the fiscal year ended December 31, 2010.
Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lara Bakhos, MD 3825 Highland Ave Ste 400, Downers Grove, IL 60515-1562 Ph: () - | Dr Lara Bakhos, MD 3825 Highland Ave, Downers Grove, IL 60515-1552 Ph: (630) 719-4799 |
News Archive
Now, new research by scientists at the University of Michigan Medical School suggests the intriguing possibility that this common virus also may play a role in prostate cancer – the second-leading cause of deaths from cancer in American men.
Efforts to understand costs and openly share information on healthcare prices played a key role in a major Arizona health system's successful turnaround from a financial crisis, according to a feature article in the Spring issue of Frontiers of Health Services Management, an official publication of the American College of Healthcare Executives.
Genalyte, Inc. announced today it has completed a Series C Financing round of $44 million, led by Khosla Ventures. The company is redefining diagnostics with a testing platform and microchip technology that can be utilized in physician offices. With the application of a single drop of blood to a silicon microchip, Genalyte's Maverick Detection System can offer a complete panel of diagnostic test results in fifteen minutes.
ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its fourth quarter and the fiscal year ended December 31, 2010.
Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.
› Verified 9 days ago
Hajira Younas Khan, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5207 Main St, Downers Grove, IL 60515 Phone: 630-435-9888 Fax: 630-963-1524 | |
Peter Michael Kerwin, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3825 Highland Ave, Tower 2 Suite 400, Downers Grove, IL 60515 Phone: 630-719-4799 | |
Dr. Kenneth P. Brin, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 3825 Highland Ave, Tower 2 - Suite 400, Downers Grove, IL 60515 Phone: 630-719-4799 | |
Stephen Michael Rowley, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3825 Highland Ave, Tower 2 Suite 400, Downers Grove, IL 60515 Phone: 630-719-4799 | |
Dr. Anil Vamsi Doppalapudi, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3825 Highland Ave Ste 3d, Downers Grove, IL 60515 Phone: 630-964-7006 Fax: 630-964-7082 | |
Mark J. Tatara, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6840 Main St Ste 200, Downers Grove, IL 60516 Phone: 630-869-5382 Fax: 630-869-5383 | |
Dr. Weiser Eguia Cordero, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5207 Main St, Downers Grove, IL 60515 Phone: 630-435-9888 Fax: 630-963-1524 |